3 years of ILUVIEN

Results presented below are from a single case; results may vary.

After treatment with ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, retinal edema was stabilized in this patient

This case was collected in Europe

  • The patient was treated with ILUVIEN® 190 micrograms intravitreal implant in applicator
  • The patient met the US labeling requirements in that they were previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP
  • In Europe, ILUVIEN is approved for the treatment of visual impairment due to chronic DME

Patient profile1

Sex: Male
Age: 64
Diagnosis: DME
Treated eye: OS
Concomitant conditions: None
Treatment history:
• 1x Corticosteroid
Notes: Pseudophakic

36-month follow-up of CST and VA in a single eye (OS) of a 64-year-old pseudophakic patient (n=1)


Real-world data from the USER Study
confirm the efficacy of ILUVIEN.


The USER Study confirms the predictable IOP
profile of ILUVIEN, when used per label.